The cost-effectiveness challenge: is it worth it?

Scarcity of resources means that difficult choices have to be made about how to use them. Cost-effectiveness evidence provides a way to help decision-makers get ‘best value’ from their resources when choosing between two or more clinical or other interventions. Often it is found that one intervention has better outcomes than another, but also costs more. In these circumstances there is a need for the decision-maker to reach a view as to whether those better outcomes are ‘worth’ the higher costs, necessitating difficult trade-offs. Illustrations from the dementia field are given to illustrate how these trade-offs might be made. For strategic decisions it has often proved helpful to use a generic outcome measure such as the quality-adjusted life year. The fundamental aim of a healthcare system is not to save money, but to save and improve lives. Cost-effectiveness and similar analyses can help by showing how to get the most out of available resources.

[1]  M. Knapp,et al.  Dementia care costs and outcomes: a systematic review , 2013, International journal of geriatric psychiatry.

[2]  Martin Knapp,et al.  Cost effectiveness of a manual based coping strategy programme in promoting the mental health of family carers of people with dementia (the START (STrAtegies for RelaTives) study): a pragmatic randomised controlled trial , 2013, BMJ.

[3]  Kia-Chong Chua,et al.  Development of DEMQOL-U and DEMQOL-PROXY-U: generation of preference-based indices from DEMQOL and DEMQOL-PROXY for use in economic evaluation. , 2013, Health technology assessment.

[4]  D. Lamping,et al.  Development of a new measure of health-related quality of life for people with dementia: DEMQOL , 2006, Psychological Medicine.

[5]  Martin Knapp,et al.  Cognitive stimulation therapy for people with dementia: cost-effectiveness analysis , 2006, British Journal of Psychiatry.

[6]  Martin Knapp,et al.  Decision making by NICE: examining the influences of evidence, process and context , 2013, Health Economics, Policy and Law.

[7]  A. Dhar,et al.  National Institute for Health and Clinical Excellence , 2005 .

[8]  G. Livingston,et al.  Clinical effectiveness of a manual based coping strategy programme (START, STrAtegies for RelaTives) in promoting the mental health of carers of family members with dementia: pragmatic randomised controlled trial , 2013, BMJ.

[9]  Stavros Petrou,et al.  Economic evaluation alongside randomised controlled trials: design, conduct, analysis, and reporting , 2011, BMJ : British Medical Journal.

[10]  Stavros Petrou,et al.  Economic evaluation using decision analytical modelling: design, conduct, analysis, and reporting , 2011, BMJ : British Medical Journal.

[11]  M. Orrell,et al.  Study of the use of antidepressants for depression in dementia: the HTA-SADD trial--a multicentre, randomised, double-blind, placebo-controlled trial of the clinical effectiveness and cost-effectiveness of sertraline and mirtazapine. , 2013, Health technology assessment.

[12]  A. Kasuya EuroQol--a new facility for the measurement of health-related quality of life. , 1990, Health policy.

[13]  A. Williams EuroQol : a new facility for the measurement of health-related quality of life , 1990 .

[14]  Bob Woods,et al.  Efficacy of an evidence-based cognitive stimulation therapy programme for people with dementia , 2003, British Journal of Psychiatry.